| Literature DB >> 10990132 |
Abstract
It is now evident that an increased amount of intra-abdominal (visceral) adipose tissue is associated with an impaired metabolic profile, increasing the risk of CVD and NIDDM. Visceral obesity also appears to be associated with impaired GH action. GH replacement therapy in patients with GHD, or GH treatment of viscerally obese individuals, is able to induce a profound reduction in the amount of visceral adipose tissue and to improve the metabolic profile.Entities:
Mesh：
Substances：
Year: 1998 PMID： 10990132 DOI： 10.1016/s1096-6374(98)80021-x
Source DB: PubMed Journal: Growth Horm IGF Res ISSN： 1096-6374 Impact factor: 2.372